Skip to main content
Premium Trial:

Request an Annual Quote

BioFocus to Offer Activiomics' Proteomics Services

NEW YORK (GenomeWeb News) – BioFocus will offer its customers Activiomics' proteomics services for identifying novel biomarkers for diagnostics and targets for new drugs, the companies said today.

Under a strategic agreement, BioFocus will offer its customers Activiomics' Targeted In-depth QUAntification of cell Signaling, or TIQUAS, technology for proteomics studies in oncology, inflammation, and metabolic disease.

Financial and other terms of the deal were not disclosed.

TIQUAS uses mass spectrometry to detect and quantify phosphorylation sites from a cell or tissue extract, which can be used to discover which proteins and pathways are activated. Changes in phosphorylation status signal a change in protein activity.

Activiomics, headquartered in London, was founded in 2009 as a private spin-out from the Barts Cancer Institute.

“Proteomics analysis, in particular phosphoproteomics, is becoming ever more important in drug discovery programs. By partnering with Activiomics, BioFocus extends its offering of high-quality scientific expertise into this newly emerging area," Chris Newton, managing director at BioFocus and senior VP of Galapagos Services, said in a statement.

BioFocus, headquartered in the UK, is a Galapagos company.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.